UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

Emmaus Life Sciences, Inc.
(Exact name of registrant as specified in its charter)

Delaware	001-35527	87-0419387
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

21250 Hawthorne Boulevard, Suite 800, Torrance, CA	90503
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (310) 214-0065

(Former name or former address, if changed, since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
None		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operation and Financial Condition.

On August 14, 2025, Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") issued a press release announcing our results of operations and financial condition as of and for the three months ended June 30, 2025, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference.

The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

See the accompanying Index to Exhibits, which is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2025

Emmaus Life Sciences, Inc.

By: /s/ WILLIS LEE
Name: Willis Lee
Title: Chairman and Chief Executive Officer

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	August 14, 2025 press release
104	Cover Page Interactive Date File (embedded within Inline XBRL document)

Exhibit 99.1

Emmaus Life Sciences Reports Quarterly Financial Results

Torrance CA, August 14, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2025.

Highlights

"We experienced a 48% decline in net revenue for three month ended June 30, 2025 as compared to the same period in 2024 due to ongoing competition from generic L-Glutamine, partially offset by a 33% reduction in operating expenses" commented Willis Lee, Chairman and Chief Executive Officer of Emmaus. "We realized loss from operations of $0.4 million compared to income from operations of $0.6 million in the prior year and achieved modest net income due to a substantial decrease in other expense," he added.

Financial and Operating Results

Net Revenues. Net revenues for the three months ended June 30, 2025 were $2.8 million, compared to $5.4 million in the same period in 2024. The decrease was due to a decrease in U.S. sales which management attributes to competition from the generic version of L-Glutamine introduced in the market in mid-2024.

Operating Expenses. Total operating expenses for the three months were $3.0 million compared to $4.6 million in the comparable period in 2024. The decrease was due primarily to decreases in selling expenses and general and administrative expenses attributable to a reduction in force in Q4 2024.

Income (Loss) From Operations. Total loss from operations for the three months was $0.4 million compared to income from operation of $0.6 million in the same period in 2024. This was due to the decrease in net revenues.

Other Expense. The company realized other expense of $1.4 million for the three months compared to $2.7 million in the same period in 2024. The decrease was due primarily to a decrease of $1.4 million in change in fair value of conversion feature derivative liabilities and an increase in decreases in $0.9 million nonrecurring gain recognized on lease modification of the Torrance headquarter office lease partially offset by $0.7 million increase in interest expenses.

Net Loss. For the three months, the company realized net loss of $1.1 million, or $0.02 per share based on approximately 63.9 million weighted-average basic common shares, compared to net loss of $2.2 million, or $0.03 per share based on approximately 63.4 million weighted-average basic common shares in the comparable period in 2024. The decreased net loss was attributable to the decrease in other expense.

Liquidity and Capital Resources. At June 30, 2025, the company had cash and cash equivalents of $0.9 million, compared to $1.4 million at December 31, 2024.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman and is available on a named patient or early access basis in France, the Netherlands, and the Kingdom of Saudi Arabia, where Emmaus' application for marketing authorization is awaiting final action by the Saudi Food & Drug Authority. For more information, please visit www.emmausmedical.com.

About Endari® (prescription grade L-glutamine oral powder)

Endari®, Emmaus' prescription grade L-glutamine oral powder, was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for treating sickle cell disease in adult and pediatric patients five years of age and older.

Indication

Endari® is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Important Safety Information

The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari® in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari® at: www.ENDARIrx.com/PI.

About Sickle Cell Disease

There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.[1] The genetic mutation responsible for SCD causes an individual's red blood cells to distort into a "C" or a sickle shape, reducing their ability to transport oxygen throughout the body. These sickled red blood cells break down rapidly, become very sticky, and develop a propensity to clump together, which causes them to become stuck and cause damage within blood vessels. The result is reduced blood flow to distal organs, which leads to physical symptoms of incapacitating pain, tissue and organ damage, and early death.[2]

Forward-looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the recent trend in net revenues . These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including doubt about the company's ability to continue as a going concern and other factors disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on April 14, 2025 and Quarterly Report on Form 10-Q filed on August 14, 2025, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.

Company Contact:

Emmaus Life Sciences, Inc.
Investor Relations
(310) 214-0065
IR@emmauslifesciences.com

1 Source: Data & Statistics on Sickle Cell Disease – National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, December 2020.

2 Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.

(Financial Tables Follow)

Emmaus Life Sciences, Inc.
Condensed Consolidated Statement of Operations and Comprehensive Income (Loss)
(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	2024	2025	2024
Revenues, Net	$ 2,817	$ 5,377	$ 5,223	$ 7,883
Cost of Goods Sold	150	241	375	498
Gross Profit	2,667	5,136	4,848	7,385
Operating Expenses	3,036	4,554	6,197	9,543
Income (Loss) from Operations	(369)	582	(1,349)	(2,158)
Total Other Expense	(1,355)	(2,735)	(2,701)	(4,350)
Net Income (Loss)	(1,134)	(2,184)	(3,464)	(6,532)
Comprehensive Income (Loss)	4,036	(1,524)	4,234	-3,234
Net Loss Per Share	$ (0.02)	$ (0.03)	$ (0.05)	$ (0.10)
Weighted Average Common Shares Outstanding	63,865,571	63,355,121	63,865,571	62,600,542

Emmaus Life Sciences, Inc.
Condensed Consolidated Balance Sheets
(In thousands)

	As of	
	June 30, 2025 (Unaudited)	December 31, 2024
Assets		
Current Assets:		
Cash and cash equivalents	$ 886	$ 1,389
Accounts receivable, net	2,071	2,623
Inventories, net	1,313	1,635
Prepaid expenses and other current assets	745	1,120
Total Current Assets	5,015	6,767
Property and Equipment, net	143	46
Right of use assets	830	1,530
Investment in convertible bond	17,188	15,037
Other Assets	168	222
Total Assets	23,344	23,602
Liabilities and Stockholders' Deficit		
Current Liabilities:		
Accounts payable and accrued expenses	19,373	16,926
Operating lease liabilities, current portion	348	2,423
Conversion feature derivative, notes payable	—	162
Notes payable, current portion	11,399	10,465
Convertible notes payable, net of discount	16,804	17,014
Other current liabilities	14,152	16,565
Total Current Liabilities	62,076	63,555
Other long-term liabilities	16,969	16,526
Total Liabilities	79,045	80,081
Stockholders' Deficit	(55,701)	(56,479)
Total Liabilities & Stockholders' Deficit	23,344	23,602